EMBARK now to gain more
Document ID: PC-ZA-101034
14/06/2021
Author: Boehringer Ingelheim
123,000
Views
100k 340
Related content
PC-ZA-101034
Production date: June 2021
Production date: June 2021
- Efficacy
- Reduction of CV death was achieved ontop of standard of care
- Early impact on risk reduction of CV death
- Relative risk reduction of CV death by more than 1/3
- Patients could live longer with Jardiance
- CV Reduction was generally consistent across baseline HbA1c
- Jardiance ONLY SGLT2 inhibitor with CV BENEFIT
- EMPA REG animation Video
- EMPA when time MEETS power
- The journey of EMPA from RCT to RWE
- The Risks of T2D
- Jardiance Cardio-Renal Benefits
- Look Beyond Metabolic Control
- Value of Time -2.5 years
- Value of Time - 4.5 years
- Reimbursement Information
- Pricing
- Budget Impact of Empagliflozin in the Treatment of Patients with T2D with eCVD in South Africa
- What is the Budget Impact study of Empagliflozin about and why was it conducted?
- Can the outcomes of the Budget Impact study be extrapolated to SGLT2-I class? Or are they Empagliflozin specific, if so why?
- Why are the NNTs extrapolated from the EMPA-REG Trial considered impressive?
- Should Empagliflozin have a more favorable position in upcoming guidelines?
- Is it fair that reimbursement is solely based on cost when studies like the Budget Impact of Empagliflozin demonstrate that other parameters should be guiding reimbursement decisions?
- Which patients should clinicians be targeting for Empagliflozin use
- Where should HCPs position Synjardy in the treatment of T2D and its complications?
- What are the overarching takeaway messages from the Budget Impact of Empagliflozin in the Treatment of Patients with T2D with eCVD in South Africa?
- Budget Impact Analysis of Empagliflozin in the Treatment of Patients With Type 2 Diabetes With Established Cardiovascular Disease in South Africa
- Value of Co-pay
- Pricing
- Tools and Guidelines
- Convenience
- Proven Efficacy